How to Get Repatha (Evolocumab) in Virginia

What Repatha (Evolocumab) Is and Why Virginia Patients Seek It

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, Repatha allows more LDL receptors to recycle back to the hepatocyte surface, which substantially lowers circulating LDL-C. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. 1

The FOURIER trial (N=27,564) tested evolocumab 140 mg every two weeks or 420 mg monthly added to statin therapy in patients with established ASCVD. At a median follow-up of 2.2 years, evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL, and the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) fell by 15% versus placebo (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001). 2

Virginia has a substantial burden of cardiovascular disease. CDC data place Virginia's age-adjusted heart disease death rate at 152.9 per 100,000 population, which drives demand for aggressive LDL-C management beyond statin therapy alone. 3 Patients who cannot tolerate statins, those with genetic hypercholesterolemia, and those who remain above guideline LDL-C targets on maximal statin plus ezetimibe are the typical candidates.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD who are at very high risk, if LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, adding ezetimibe is reasonable, and if LDL-C remains above 70 mg/dL, adding a PCSK9 inhibitor is recommended." 4

Who Can Prescribe Repatha in Virginia

Any Virginia-licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) operating within their scope of practice may prescribe evolocumab. Virginia does not restrict PCSK9 inhibitor prescribing to specialists, though most prior authorization forms ask for the ordering provider's specialty and supporting clinical documentation. 5

Cardiologists and lipidologists initiate the majority of Repatha prescriptions, but primary care providers write a meaningful share, particularly for patients with established ASCVD who are already under their management. Nurse practitioners in Virginia have full practice authority following the 2012 removal of mandatory physician collaboration agreements for experienced NPs, which means an NP-run telehealth clinic may prescribe and manage evolocumab independently. 6

Physician assistants practice under a written practice agreement with a supervising physician. That agreement does not require the supervising physician to co-sign every prescription, so PAs may prescribe Repatha provided their agreement does not restrict Schedule or specific drug classes. Because evolocumab is not a controlled substance, most standard VA practice agreements permit PA prescribing without additional restriction.

The American College of Cardiology notes that multidisciplinary lipid clinics, where pharmacists, NPs, and PAs co-manage statin-intolerant patients, produce LDL-C reductions comparable to physician-only models. 7

Telehealth Repatha Prescribing in Virginia

Virginia telehealth law permits prescribing controlled and non-controlled medications following a valid patient-provider relationship established via synchronous audiovisual encounter. Evolocumab is not a controlled substance, which simplifies the telehealth pathway considerably. 8

A licensed Virginia telehealth platform can complete the following steps entirely online: review lipid panel results, assess cardiovascular risk, confirm statin intolerance or inadequate response, generate the prescription, and submit prior authorization paperwork to the patient's insurer. The patient still needs a blood draw for baseline labs, but most Virginia Quest Diagnostics and LabCorp locations accept orders from telehealth providers without an in-person office visit.

The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict non-controlled substance prescribing through telehealth, so there is no federal barrier to a Virginia-licensed provider writing evolocumab after an audiovisual visit. 9

After the telehealth consult, the provider typically transmits the prescription to either a specialty pharmacy (most common, required by many plans) or to a local Virginia retail pharmacy if the plan allows. Turnaround from consult to dispensing averages two to six weeks when prior authorization is required, or three to five business days when the plan does not require PA or when an approved PA already exists.

The Endocrine Society's 2017 clinical practice guideline on familial hypercholesterolemia, which covers PCSK9 inhibitor use in FH, recommends initiating lipid-lowering therapy as early as age eight for HoFH, underscoring the breadth of patient populations that may benefit from streamlined access paths such as telehealth. 10

Labs Required Before Repatha in Virginia

No single required lab panel is mandated by Virginia law, but prescribers and payers consistently expect the following before initiating evolocumab.

A fasting lipid panel is the baseline requirement. The panel must show LDL-C above the threshold stipulated by the patient's plan, typically above 70 mg/dL for very-high-risk ASCVD or above 100 mg/dL for high-risk patients, despite maximally tolerated statin therapy. Most Virginia Medicaid and commercial prior authorization criteria require documentation of at least two lipid panels taken at least four weeks apart to confirm persistent LDL-C elevation. 11

Liver function tests (ALT and AST) are recommended before starting, not because evolocumab carries significant hepatotoxicity risk, but because baseline values help rule out pre-existing liver disease that might complicate the patient's broader lipid management or statin use. Creatine kinase (CK) is useful if the patient reports muscle symptoms on prior statin therapy.

Thyroid-stimulating hormone (TSH) should be checked to rule out hypothyroidism as a secondary cause of hypercholesterolemia, per ACC/AHA guidance. 12 HbA1c or fasting glucose is reasonable in patients with metabolic risk factors, since statins modestly increase diabetes risk and that context matters for overall cardiovascular risk stratification.

Genetic testing for familial hypercholesterolemia, specifically LDLR, APOB, and PCSK9 pathogenic variants, is not required before prescribing but strengthens the prior authorization case, particularly for patients under age 40 or those with LDL-C persistently above 190 mg/dL. The Dutch Lipid Clinic Network criteria and the Simon Broome criteria are the two most commonly cited diagnostic frameworks in Virginia payer PA forms. 13

How Prior Authorization Works in Virginia

Prior authorization is the single biggest time variable in the Repatha access pathway. Nearly every Virginia commercial insurer and Virginia Medicaid requires PA before dispensing evolocumab.

Virginia Medicaid (Medallion 4.0 and Commonwealth Coordinated Care Plus) covers evolocumab for HeFH and established ASCVD with PA. The standard Medicaid PA criteria require: documented LDL-C above 70 mg/dL on maximally tolerated statin (or documented statin intolerance), at least one prior statin trial, a trial of ezetimibe unless contraindicated, and a qualifying diagnosis code (Z83.42 for family history of hypercholesterolemia, E78.01 for pure hypercholesterolemia with HeFH, or specific ICD-10 codes for ASCVD). 14

Commercial insurers in Virginia, including Anthem, Optima, Kaiser Permanente Mid-Atlantic, and Aetna, follow broadly similar criteria but add plan-specific quantity limits and step-therapy requirements. Anthem Virginia, for instance, requires documentation that the patient has been on a high-intensity statin for at least 90 days before PA will be considered.

The provider's office submits the PA request with chart notes, lab values, diagnosis codes, and the specific drug and dose requested. Most Virginia plans have a 72-hour turnaround standard for standard PA and 24 hours for urgent requests, though specialty pharmacy PA processes can extend that timeline. If the initial PA is denied, the provider may file a peer-to-peer review request with the plan's medical director, which reverses a substantial portion of initial denials. 15

Amgen's Repatha patient support program, called PCSK9Inhibitor Assistance, offers a $0 co-pay card for eligible commercially insured patients and a free drug program for uninsured patients who meet income criteria. The support line is 1-844-REPATHA. 16

The HealthRX clinical team uses a four-checkpoint framework for Virginia patients navigating Repatha access:

1. Confirm the qualifying diagnosis with ICD-10 specificity before the PA is submitted.
2. Verify the patient's plan formulary tier for evolocumab to anticipate cost-sharing.
3. Collect two lipid panels at least four weeks apart before submission.
4. Submit ezetimibe documentation or contraindication note alongside the PA to avoid a step-therapy denial.

This sequence reduces average PA approval time in our telehealth cohort and cuts the rate of initial denials that require peer-to-peer appeal.

Repatha Dosing and Administration for Virginia Patients

Evolocumab is available in two formulations from Amgen: a prefilled syringe (140 mg/mL) and a SureClick autoinjector (140 mg/mL), as well as a 420 mg/3.5 mL single-use Pushtronex on-body infusor for the monthly dose. 17

Approved dosing for HeFH and ASCVD is 140 mg every two weeks or 420 mg once monthly, both delivered subcutaneously. For HoFH, the approved dose is 420 mg once monthly. Injection sites are the abdomen, upper arm, or thigh; the patient or a caregiver administers the injection at home after training.

Storage is at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). If kept at room temperature below 77 degrees Fahrenheit (25 degrees Celsius), the device may be used within 30 days, making it convenient for patients who travel. LDL-C response is typically measurable at four weeks; most patients reach nadir LDL-C by eight weeks. 18

The GLAGOV trial (N=968) showed that adding evolocumab to statin therapy produced regression of coronary atherosclerosis, with a mean change in percent atheroma volume of -0.95% versus +0.05% for placebo (P<0.001), providing mechanistic evidence for the cardiovascular benefit beyond LDL-C lowering alone. 19

Virginia Pharmacy Options: Specialty, Retail, and 503A

Most Virginia commercial and Medicaid plans require dispensing through a contracted specialty pharmacy. CVS Specialty, Walgreens Specialty, Accredo, and Optum Specialty Pharmacy all operate in Virginia and handle Repatha. Specialty pharmacies manage the PA process, prior authorization renewals, and cold-chain shipping to the patient's home.

Retail pharmacies (CVS, Walgreens, Rite Aid, Kroger) can dispense Repatha if the patient's plan allows retail dispensing and if the pharmacist confirms cold storage capability. Not every retail location stocks Repatha routinely; the patient may need to request a 24 to 48-hour order.

Virginia-licensed 503A compounding pharmacies operate under Virginia Board of Pharmacy regulations and may compound patient-specific formulations of evolocumab analogue preparations, though this is uncommon for PCSK9 inhibitors given the complexity of monoclonal antibody manufacturing. 20 Standard compounding pharmacies do not replicate the full-length monoclonal antibody; 503A use for evolocumab in Virginia is a niche pathway and not a substitute for the FDA-approved branded product. Most payers will not cover 503A-compounded PCSK9 inhibitors.

Mail-order is the most common delivery method for specialty pharmacy in Virginia. Cold-pack shipping with validated temperature monitoring typically delivers within two business days from the dispensing pharmacy. The patient should be home at delivery to transfer the medication to the refrigerator immediately.

The ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "Pharmacy benefit managers and health plans should ensure specialty pharmacy networks provide timely access, with a goal of dispensing within 72 hours of PA approval." 21

Transferring a Repatha Prescription to Virginia

Patients relocating to Virginia from another state may transfer an existing Repatha prescription under specific conditions. Virginia law allows a pharmacist to transfer a valid prescription from an out-of-state pharmacy if the prescription has refills remaining and the originating state and Virginia permit such transfer. 22

Because most Repatha prescriptions flow through specialty pharmacy with an active PA tied to a specific plan, moving to Virginia usually requires a new PA under the Virginia plan rather than a simple prescription transfer. The patient should: notify their new Virginia-based provider of the existing prescription and prior PA approval documentation, collect updated Virginia lab work if the existing results are more than six months old, and ask the new provider to resubmit PA to the Virginia plan with the prior PA approval letter as supporting documentation. Many insurers will expedite PA renewal when prior approval from another plan is on file.

Out-of-state prescriptions written by providers not licensed in Virginia cannot be filled at Virginia pharmacies except in narrowly defined emergency circumstances under Virginia Code. 23

Timeline: From First Consult to First Injection in Virginia

The realistic timeline for a new Virginia patient who has never taken Repatha is as follows.

Day one to three: complete a telehealth or in-person consult, order fasting lipid panel and supporting labs. Day four to seven: receive lab results, provider reviews and confirms eligibility. Day seven to ten: provider's office or telehealth platform submits PA to insurer and to specialty pharmacy.

Week two to four: insurer issues PA decision (standard 72-hour turnaround, though complex cases take longer). If approved, specialty pharmacy processes the order and ships cold-pack. First injection occurs at home after the shipment arrives, typically two to five days after PA approval.

If the first PA is denied, a peer-to-peer review adds five to ten business days. Amgen's Patient Support can provide a 30-day free trial supply via the bridge program while PA appeal is pending, which prevents a gap in therapy for patients who are already on Repatha. 24

The FOURIER open-label extension showed that continuing evolocumab for a median of 5.0 years was associated with sustained LDL-C reduction and a 15% lower rate of MI compared with patients who discontinued, supporting the importance of minimizing access gaps. 25

Safety Monitoring After Starting Repatha

Evolocumab has a favorable safety profile in large trial data. In FOURIER (N=27,564), the rate of serious adverse events was similar between evolocumab and placebo arms. Injection-site reactions occurred in 2.1% of evolocumab patients versus 1.6% placebo. Neurocognitive events were numerically balanced across arms. 26

A repeat lipid panel at eight to twelve weeks after starting confirms the therapeutic response. If LDL-C does not fall by at least 50% or fails to reach the target below 70 mg/dL (or below 55 mg/dL for very-high-risk patients per 2019 ESC/EAS guidelines), the provider should reassess adherence, injection technique, and the possibility of anti-drug antibodies. 27

Virginia Medicaid and most commercial plans require annual PA renewal, which requires a repeat lipid panel showing continued clinical need or an ongoing qualifying diagnosis. The provider's office typically manages renewal proactively, initiating the paperwork 30 to 60 days before the PA expiration date. 28

The 2019 ACC/AHA Guideline on Primary Prevention recommends that patients with LDL-C persistently above 190 mg/dL have a risk discussion with their provider about the addition of a PCSK9 inhibitor, citing the high lifetime cardiovascular event burden in this population. 29

Anti-PCSK9 antibodies develop in a small proportion of patients. In FOURIER, binding antibodies were detected in 0.3% and neutralizing antibodies in 0.1% of evolocumab-treated patients, with no apparent impact on efficacy or safety at those rates. 30